dnib0600a (lifastuzumab vedotin) Search Results


lifastuzumab vedotin rg-7599 or dnib0600a  (Genentech inc)
90
Genentech inc lifastuzumab vedotin rg-7599 or dnib0600a
Approved ADCs in clinical use.
Lifastuzumab Vedotin Rg 7599 Or Dnib0600a, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dnib0600a+(lifastuzumab+vedotin)/dnib0600a/pmc05769674-21-0-6
Average 90 stars, based on 1 article reviews
lifastuzumab vedotin rg-7599 or dnib0600a - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Approved ADCs in clinical use.

Journal: Oncoimmunology

Article Title: Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)

doi: 10.1080/2162402X.2017.1395127

Figure Lengend Snippet: Approved ADCs in clinical use.

Article Snippet: Lifastuzumab vedotin (RG-7599 or DNIB0600A) , Genentech/Roche , Ovarian cancer, Non-small cell lung cancer , NaPi2b , Humanised IgG1 , Vc-PAB , MMAE , II, NCT01991210 (completed).

Techniques: Recombinant

ADCs in clinical development in Phase I/II, II or III (U.S. National Institutes of Health. Clinical trials. at https://clinicaltrials.gov ).

Journal: Oncoimmunology

Article Title: Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)

doi: 10.1080/2162402X.2017.1395127

Figure Lengend Snippet: ADCs in clinical development in Phase I/II, II or III (U.S. National Institutes of Health. Clinical trials. at https://clinicaltrials.gov ).

Article Snippet: Lifastuzumab vedotin (RG-7599 or DNIB0600A) , Genentech/Roche , Ovarian cancer, Non-small cell lung cancer , NaPi2b , Humanised IgG1 , Vc-PAB , MMAE , II, NCT01991210 (completed).

Techniques: Clinical Proteomics, Immunopeptidomics, Amplification, Recombinant, Control, Expressing